On August 13, 2025, ARS Pharmaceuticals received a notice from Lupin Inc. indicating that Lupin has filed for FDA approval to sell a generic version of the company's epinephrine nasal spray, neffy, potentially infringing on several existing patents. This filing could lead to a legal battle as ARS intends to defend its patents within the 45-day period provided for filing a lawsuit.